Compositions and methods for treating IgE-mediated disorders

• US 9,617,348 B2
• Filed: 04/10/2013
• Issued: 04/11/2017
• Est. Priority Date: 03/26/2004
• Status: Active Grant

• Current Assignee: Xencor, Inc.
• Original Assignee: Xencor, Inc.
• Inventors: Desjarlais, John R., Chu, Seung Y., Horton, Holly M., Bernett, Matthew J.
• Primary Examiner(s): SZPERKA, MICHAEL EDWARD
• Application Number:
  US13/860,500
• Publication Number:
  US 20130203967A1
• Time in Patent Office: 1,462 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C07K 16/4291 against IgE
• CPC Class Codes: C07K 16/464 Igs containing CDR-residues from one specie grafted between FR-residues from another
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.

Claims

1. An antibody comprising:

a) a heavy chain comprising;

i) heavy chain variable region comprising SEQ ID NO;

17; and

ii) a variant Fc domain of a human parent IgG Fc polypeptide; and

b) a light chain comprising a light chain variable region comprising SEQ ID NO;

21,

wherein said variant Fc region has increased binding to Fcγ

IIb relative to said human parent IgG Fc polypeptide.

2. The antibody of claim 1, wherein said human parent IgG polypeptide is an IgG1 polypeptide.

3. The antibody of claim 1, wherein said antibody is selected from the group consisting of a chimeric antibody, a humanized antibody, and a monoclonal antibody.